Pancreatic Beta-Cell Proliferation Induced by Estradiol-17β is Foxo1 Dependent

Abstract

Estradiol-17β (E2) and the Foxo1 transcription factor have each been implicated in the regulation of β-cell proliferation. Interaction between Foxo1and estrogen receptor alpha (ERα), effecting cell cycle, has been demonstrated in breast cancer cells, but has not been studied thus far in β-cells. Using human islets and the INS1-E β-cell line, this study investigated the contribution of Foxo1 to E2-mediated β-cell replication. Foxo1 expression was knocked down in INS1-E cells using siRNA and Foxo1 activity was inhibited in human islets with a specific Foxo1 inhibitor (AS1842856). Cells were treated with E2 and the ERα agonist PPT and evaluated for proliferation by ³[H]-thymidine incorporation and for transcriptional activity through the estrogen response element by the luciferase assay. As Foxo1 activity is regulated by post-translational modifications, the effect of E2 on phosphorylation was also assessed. In INS1-E cells, knock down of Foxo1 abrogated the proliferative response to E2 and PPT. In human islets, inhibition of Foxo1 abrogated E2-mediated proliferation and attenuated the response to PPT. Foxo1 knock down and inhibition reduced activity through the estrogen response element by 25% (p<0.05) and 50% (p<0.01) respectively, in INS1-E cells. E2 increased Foxo1 phosphorylation in a time dependent manner in INS1-E and human islets (p<0.01, p<0.05, respectively). These findings suggest that Foxo1 is involved in E2-mediated proliferation in INS1-E cells and human islets. This may have implications vis-à-vis variations in circulating endogenous E2 concentrations in diabetes.

Key words

estrogen - diabetes - replication

• References

• 1 Andersson B, Mattsson LA, Hahn L, Marin P, Lapidus L, Holm G, Bengtsson BA, Bjorntorp P. Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82: 638-643
• 2 Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, Burke G, Torrens J, Howard BV. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: Results from the women's health initiative hormone trial. Diabetologia 2004; 47: 1175-1187
• 3 Paik SG, Michelis MA, Kim YT, Shin S. Induction of insulin-dependent diabetes by streptozotocin. Inhibition by estrogens and potentiation by androgens. Diabetes 1982; 31: 724-729
• 4 Clark JB, Palmer CJ, Shaw WN. The diabetic zucker fatty rat. Proc Soc Exp Biol Med 1983; 173: 68-75
• 5 Russell AL, Grimes JM, Cruthirds DF, Westerfield J, Wooten L, Keil M, Weiser MJ, Landauer MR, Handa RJ, Wu TJ, Larco DO. Dietary isoflavone-dependent and estradiol replacement effects on body weight in the ovariectomized (ovx) rat. Horm Metab Res 2017; 49: 457-465
• 6 Louet JF, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: Insight from human and genetic mouse models. Curr Atheroscler Rep 2004; 6: 180-185
• 7 Tiano JP, Mauvais-Jarvis F. Importance of oestrogen receptors to preserve functional beta-cell mass in diabetes. Nat Rev Endocrinol 2012; 8: 342-351
• 8 Yuchi Y, Cai Y, Legein B, De Groef S, Leuckx G, Coppens V, Van Overmeire E, Staels W, De Leu N, Martens G, Van Ginderachter JA, Heimberg H, Van de Casteele M. Estrogen receptor alpha regulates beta-cell formation during pancreas development and following injury. Diabetes 2015; 64: 3218-3228
• 9 Bernal-Mizrachi E, Kulkarni RN, Scott DK, Mauvais-Jarvis F, Stewart AF, Garcia-Ocana A. Human beta-cell proliferation and intracellular signaling part 2: Still driving in the dark without a road map. Diabetes 2014; 63: 819-831
• 10 Kumar R, Balhuizen A, Amisten S, Lundquist I, Salehi A. Insulinotropic and antidiabetic effects of 17beta-estradiol and the gpr30 agonist g-1 on human pancreatic islets. Endocrinology 2011; 152: 2568-2579
• 11 Liu S, Le May C, Wong WP, Ward RD, Clegg DJ, Marcelli M, Korach KS, Mauvais-Jarvis F. Importance of extranuclear estrogen receptor-alpha and membrane g protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 2009; 58: 2292-2302
• 12 Liu S, Mauvais-Jarvis F. Rapid, nongenomic estrogen actions protect pancreatic islet survival. Islets 2009; 1: 273-275
• 13 Ren Z, Zou C, Ji H, Zhang Y. Oestrogen regulates proliferation and differentiation of human islet-derived precursor cells through oestrogen receptor alpha. Cell Biol Int 2010; 34: 523-530
• 14 Sharma G, Prossnitz ER. Mechanisms of estradiol-induced insulin secretion by the g protein-coupled estrogen receptor gpr30/gper in pancreatic beta-cells. Endocrinology 2011; 152: 3030-3039
• 15 Liu S, Kilic G, Meyers MS, Navarro G, Wang Y, Oberholzer J, Mauvais-Jarvis F. Oestrogens improve human pancreatic islet transplantation in a mouse model of insulin deficient diabetes. Diabetologia 2013; 56: 370-381
• 16 Kitamura YI, Kitamura T, Kruse JP, Raum JC, Stein R, Gu W, Accili D. Foxo1 protects against pancreatic beta cell failure through neurod and mafa induction. Cell Metab 2005; 2: 153-163
• 17 Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 2012; 150: 1223-1234
• 18 Nemoto S, Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002; 295: 2450-2452
• 19 Medema RH, Kops GJ, Bos JL, Burgering BM. Afx-like forkhead transcription factors mediate cell-cycle regulation by ras and pkb through p27kip1. Nature 2000; 404: 782-787
• 20 Talchai C, Xuan S, Kitamura T, DePinho RA, Accili D. Generation of functional insulin-producing cells in the gut by foxo1 ablation. Nat Genet 2012; 44: 406-412 S401
• 21 Bouchi R, Foo KS, Hua H, Tsuchiya K, Ohmura Y, Sandoval PR, Ratner LE, Egli D, Leibel RL, Accili D. Foxo1 inhibition yields functional insulin-producing cells in human gut organoid cultures. Nat Commun 2014; 5: 4242
• 22 Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, Sharpless NE. P16ink4a induces an age-dependent decline in islet regenerative potential. Nature 2006; 443: 453-457
• 23 Kitamura T, Nakae J, Kitamura Y, Kido Y, Biggs 3rd WH, Wright CV, White MF, Arden KC, Accili D. The forkhead transcription factor foxo1 links insulin signaling to pdx1 regulation of pancreatic beta cell growth. J Clin Invest 2002; 110: 1839-1847
• 24 Hashimoto N, Kido Y, Uchida T, Asahara S, Shigeyama Y, Matsuda T, Takeda A, Tsuchihashi D, Nishizawa A, Ogawa W, Fujimoto Y, Okamura H, Arden KC, Herrera PL, Noda T, Kasuga M. Ablation of pdk1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat Genet 2006; 38: 589-593
• 25 Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 1999; 96: 857-868
• 26 Schuur ER, Loktev AV, Sharma M, Sun Z, Roth RA, Weigel RJ. Ligand-dependent interaction of estrogen receptor-alpha with members of the forkhead transcription factor family. J Biol Chem 2001; 276: 33554-33560
• 27 Shaklai S, Shefer G, Stern N. Glucose-dependent foxo1 switch in healing wounds: A shred of hope for diabetic ulcers?. Diabetes 2015; 64: 6-8
• 28 Lyu J, Imachi H, Iwama H, Zhang H, Murao K. Insulin-like growth factor 1 regulates the expression of atp-binding cassette transporter a1 in pancreatic beta cells. Horm Metab Res 2016; 48: 338-344
• 29 Zhao HH, Herrera RE, Coronado-Heinsohn E, Yang MC, Ludes-Meyers JH, Seybold-Tilson KJ, Nawaz Z, Yee D, Barr FG, Diab SG, Brown PH, Fuqua SA, Osborne CK. Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem 2001; 276: 27907-27912
• 30 Tie L, An Y, Han J, Xiao Y, Xiaokaiti Y, Fan S, Liu S, Chen AF, Li X. Genistein accelerates refractory wound healing by suppressing superoxide and foxo1/inos pathway in type 1 diabetes. J Nutr Biochem 2013; 24: 88-96
• 31 Won CK, Ji HH, Koh PO. Estradiol prevents the focal cerebral ischemic injury-induced decrease of forkhead transcription factors phosphorylation. Neurosci Lett 2006; 398: 39-43
• 32 Foulds CE, Feng Q, Ding C, Bailey S, Hunsaker TL, Malovannaya A, Hamilton RA, Gates LA, Zhang Z, Li C, Chan D, Bajaj A, Callaway CG, Edwards DP, Lonard DM, Tsai SY, Tsai MJ, Qin J, O'Malley BW. Proteomic analysis of coregulators bound to eralpha on DNA and nucleosomes reveals coregulator dynamics. Mol Cell 2013; 51: 185-199
• 33 Greenman Y, Grafi-Cohen M, Sharon O, Knoll E, Kohen F, Stern N, Somjen D. Anti-proliferative effects of a novel isoflavone derivative in medullary thyroid carcinoma: An in vitro study. J Steroid Biochem Mol Biol 2012; 132: 256-261
• 34 Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, Shimokawa T, Shibasaki M. Discovery of novel forkhead box o1 inhibitors for treating type 2 diabetes: Improvement of fasting glycemia in diabetic db/db mice. Mol Pharmacol 2010; 78: 961-970
• 35 Kobayashi M, Kikuchi O, Sasaki T, Kim HJ, Yokota-Hashimoto H, Lee YS, Amano K, Kitazumi T, Susanti VY, Kitamura YI, Kitamura T. Foxo1 as a double-edged sword in the pancreas: Analysis of pancreas- and beta-cell-specific foxo1 knockout mice. Am J Physiol Endocrinol Metab 2011; 302: E603-E613